2020
DOI: 10.1016/j.ijpharm.2020.119253
|View full text |Cite
|
Sign up to set email alerts
|

Terahertz-spectroscopy for non-destructive determination of crystallinity of L-tartaric acid in smartFilms® and tablets made from paper

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
7
0

Year Published

2020
2020
2025
2025

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 16 publications
(7 citation statements)
references
References 50 publications
0
7
0
Order By: Relevance
“…Porosity and drug mass fraction Indomethacin [217] Crystallinity L-tartaric acid [218] Analysis of inner structure of tablets incorporated with pellets Theophylline [219] Nuclear magnetic resonance imaging…”
Section: Terahertz Pulsed Imagingmentioning
confidence: 99%
See 1 more Smart Citation
“…Porosity and drug mass fraction Indomethacin [217] Crystallinity L-tartaric acid [218] Analysis of inner structure of tablets incorporated with pellets Theophylline [219] Nuclear magnetic resonance imaging…”
Section: Terahertz Pulsed Imagingmentioning
confidence: 99%
“…Terahertz pulsed imaging utilizes non-ionizing radiations to record the refractive index and physicochemical features of the tablet mass without inducing thermal stress within the sample. Terahertz pulsed imaging has been employed to evaluate crystallinity, polymorphism, density distribution, hardness, porosity, drug content and microstructure of tablets [192,218,238,239]. Moreover, terahertz pulsed imaging has been used to measure tablet coating thickness (Figure 4D) [240].…”
Section: Terahertz Pulsed Imagingmentioning
confidence: 99%
“…The production of smartFilms includes three main steps: first, the dissolution of the API in an appropriate (organic) solvent; second, the application of the solution on a cellulose-based paper matrix; and, finally, the drying of the obtained smartFilms. The resulting smartFilms can be easily transferred into convenient oral dosage forms, such as capsules or tablets, fulfilling the requirements of the European Pharmacopoeia [ 8 , 9 , 10 ]. The key problem of amorphous formulations is the physical instability of the amorphous state which can lead to recrystallization and consequently unpredictable and decreased solubility and, thus, insufficient bioavailability [ 2 ].…”
Section: Introductionmentioning
confidence: 99%
“…Due to this, the transfer of the smartFilms into appropriate oral dosage forms is important for improving patient compliance. Several studies already reported the successful compression of drug-loaded smartFilms into tablets without the addition of any excipients and demonstrated that the produced tablets fulfilled all requirements of the European Pharmacopeia [ 4 , 5 , 6 ].…”
Section: Introductionmentioning
confidence: 99%